{"news_desk": "Business", "print_page": "3", "section_name": "The Upshot", "subsection_name": null, "document_type": "article", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2015/01/14/upshot/08UP--Drugs-1/08UP--Drugs-1-thumbStandard.jpg"}], "abstract": "The Upshot; ProPublica analysis of information contained in database known as Open Payments shows that drugs most aggressively marketed to doctors are not typically cures or medical breakthroughs, but new drugs that manufacturers hope will gain foothold; analysis is first comprehensive examination of how much money drug companies have spent in working with doctors.", "type_of_material": "News", "word_count": "1314", "lead_paragraph": "The money spent to influence doctors tends to be in the service of newer drugs that are &#8220;fairly redundant.&#8221;", "pub_date": "2015-01-08T00:00:00Z", "_id": "54ad823a38f0d817e02e6e46", "byline": {"contributor": "", "original": "By CHARLES ORNSTEIN and RYANN GROCHOWSKI JONES", "person": [{"rank": 1, "role": "reported", "firstname": "Charles", "organization": "", "lastname": "ORNSTEIN"}, {"middlename": "Grochowski", "firstname": "Ryann", "lastname": "JONES", "rank": 2, "role": "reported", "organization": ""}]}, "source": "The New York Times", "snippet": "The money spent to influence doctors tends to be in the service of newer drugs that are &#8220;fairly redundant.&#8221;", "web_url": "http://www.nytimes.com/2015/01/08/upshot/the-drugs-that-companies-promote-to-doctors-are-rarely-breakthroughs.html", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Doctors", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "ProPublica", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Hospitals", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Eliquis (Drug)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Pradaxa (Drug)", "name": "subject"}], "headline": {"main": "The Drugs That Companies Promote to Doctors Are Rarely Breakthroughs", "content_kicker": "Public Health", "print_headline": "Analyzing Drugs That Are Most Promoted to Doctors", "kicker": "The Upshot"}}